<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02806141</url>
  </required_header>
  <id_info>
    <org_study_id>HatYaiMec-Neonate</org_study_id>
    <nct_id>NCT02806141</nct_id>
  </id_info>
  <brief_title>Aerosolized Plus Intravenous vs. Intravenous Colistin for VAP Due to Pandrugs-resistant A. Baumannii in Neonates</brief_title>
  <official_title>Aerosolized Plus Intravenous Colistin Compared With Intravenous Colistin for Adjunctive Treatment of Ventilator-associated Pneumonia Due to Pandrugs-resistant Acinetobacter Baumannii in the Neonates: Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hat Yai Medical Education Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hat Yai Medical Education Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is planned to compare the clinical efficacy and safety of aerosolized plus
      intravenous colistin vs. intravenous colistin as adjunctive therapy for the treatment of
      ventilator-associated pneumonia (VAP) due to pandrugs-resistant (PDR) Acinetobacter baumannii
      in the neonates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the neonates with VAP due to PDR-Acinetobacter baumannii who receive
      aerosolized plus intravenous colistin compare with intravenous colistin as adjunctive
      therapy. The efficacy and safety after study will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Cure</measure>
    <time_frame>Through study completion, an average of 2 weeks</time_frame>
    <description>Clinical outcome is classified in 4 categories: Cure, Improved, Failure, and Death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Improved</measure>
    <time_frame>Through study completion, an average of 2 weeks</time_frame>
    <description>Clinical outcome is classified in 4 categories: Cure, Improved, Failure, and Death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Failure</measure>
    <time_frame>Through study completion, an average of 2 weeks</time_frame>
    <description>Clinical outcome is classified in 4 categories: Cure, Improved, Failure, and Death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Death</measure>
    <time_frame>Through study completion, an average of 2 weeks</time_frame>
    <description>Clinical outcome is classified in 4 categories: Cure, Improved, Failure, and Death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Eradication</measure>
    <time_frame>Through study completion, an average of 2 weeks</time_frame>
    <description>Microbiological response is classified in 3 categories: Eradication Persistence, Superinfection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Persistence</measure>
    <time_frame>Through study completion, an average of 2 weeks</time_frame>
    <description>Microbiological response is classified in 3 categories: Eradication Persistence, Superinfection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Superinfection</measure>
    <time_frame>Through study completion, an average of 2 weeks</time_frame>
    <description>Microbiological response is classified in 3 categories: Eradication Persistence, Superinfection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events That Are Related to Study Drug</measure>
    <time_frame>Through study completion, an average of 4 weeks</time_frame>
    <description>Number of Patients With Adverse Events That Are Related to Study Drug, Graded According to NCI CTCAE Version 3.0 focus on neurology, pulmonology, nephrology and metabolic/laboratory.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Pneumonia, Ventilator-Associated</condition>
  <condition>Colistin Adverse Reaction</condition>
  <condition>Infection Due to Multidrug Resistant Acinetobacter</condition>
  <condition>Infection Resistant to Multiple Drugs</condition>
  <arm_group>
    <arm_group_label>Aerosolized plus intravenous colistin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neonates with VAP due to PDR-A. baumannii who receive aerosolized colistin (4 mg/kg/dose twice daily) plus intravenous colistin (3.5 mg/kg/dose twice daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous colistin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neonates with VAP due to PDR-A. baumannii who receive only intravenous colistin (3.5 mg/kg/dose twice daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aerosolized plus intravenous colistin</intervention_name>
    <description>Aerosolized colistin at the dose of 4 mg colistin base activity (CBA)/kg twice daily (8 mg/kg/day) plus intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)</description>
    <arm_group_label>Aerosolized plus intravenous colistin</arm_group_label>
    <other_name>colistimethate sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous colistin</intervention_name>
    <description>Intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)</description>
    <arm_group_label>Intravenous colistin</arm_group_label>
    <other_name>colistimethate sodium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Neonates who are admitted to the neonatal intensive care unit, Hat Yai Hospital during
             the study period.

          -  Neonates who were complicated with VAP due to PDR-Acinetobacter baumannii susceptible
             to colistin (by minimal inhibitory concentration (MIC) &lt; 2 mcg/dL).

        Exclusion Criteria:

          -  Neonates who have a major anomaly or chromosomal abnormality.

          -  Neonates who receive colistin prior 7 days prior to study.

          -  Neonates who have a significant renal dysfunction defined as a serum creatinine (SCr)
             &gt;1.5 mg/dL or a decrease in urine output to &lt; 1 mL/kg/h;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Narongsak Nakwan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hat Yai Medical Education Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Narongsak Nakwan, MD</last_name>
    <phone>66818980546</phone>
    <email>nnakwan@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Narongwit Nakwan, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Narongsak Nakwan</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkhla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Narongsak Nakwan, MD</last_name>
      <phone>668189801546</phone>
      <email>nnakwan@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Nakwan N, Wannaro J, Thongmak T, Pornladnum P, Saksawad R, Nakwan N, Chokephaibulkit K. Safety in treatment of ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii with aerosolized colistin in neonates: a preliminary report. Pediatr Pulmonol. 2011 Jan;46(1):60-6. doi: 10.1002/ppul.21324. Epub 2010 Sep 1.</citation>
    <PMID>20812247</PMID>
  </reference>
  <reference>
    <citation>Nakwan N, Lertpichaluk P, Chokephaibulkit K, Villani P, Regazzi M, Imberti R. Pulmonary and Systemic Pharmacokinetics of Colistin Following a Single Dose of Nebulized Colistimethate in Mechanically Ventilated Neonates. Pediatr Infect Dis J. 2015 Sep;34(9):961-3. doi: 10.1097/INF.0000000000000775.</citation>
    <PMID>26065861</PMID>
  </reference>
  <reference>
    <citation>Nakwan N, Usaha S, Chokephaibulkit K, Villani P, Regazzi M, Imberti R. Pharmacokinetics of Colistin Following a Single Dose of Intravenous Colistimethate Sodium in Critically Ill Neonates. Pediatr Infect Dis J. 2016 Nov;35(11):1211-1214.</citation>
    <PMID>27276179</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2016</study_first_submitted>
  <study_first_submitted_qc>June 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2016</study_first_posted>
  <last_update_submitted>September 19, 2016</last_update_submitted>
  <last_update_submitted_qc>September 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hat Yai Medical Education Center</investigator_affiliation>
    <investigator_full_name>Dr. Narongsak Nakwan</investigator_full_name>
    <investigator_title>Head of Division of Neonatalogy, Department of Pediatrics, Hat Yai Hospital</investigator_title>
  </responsible_party>
  <keyword>Aerosolized colistin</keyword>
  <keyword>Intravenous colistin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colistin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

